上海医药(02607.HK)子公司参建合营 现金出资2亿美元
上海医药(02607.HK)(601607.SH)公布,全资子公司SPH PB与BIOCAD HK正式签署《上海医药与BIOCAD间合资协议》与《关於SPH-BIOCAD(HK)Limited的股东协议》,将合资新设合资公司,注册资本金4亿美元。
SPH PB以现金出资约2亿美元,占合资公司50.1%股权;BIOCAD HK以现金2,994万美元及6个合作产品在内地及港澳台的永久、独家的研发、生产、销售及其他商业化权利,共计出资近2亿美元,占合资公司49.9%股权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.